ArticleCancer immunology, immunotherapy : CII2026
Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study.
Yaofei Jiang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.